189060-13-7

Basic information

• Product Name: LAPAQUISTAT
• Synonyms: LAPAQUISTAT;Lapaquistat and Lapaquistat Acetate;Lapaquistat Acetate;2-[1-[2-[1-(3-Acetoxy-2,2-diMethylpropyl)-7-chloro-5(S)-(2,3-diMethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3(R)-yl]acetyl]piperidin-4-yl]acetic acid;TAK-475;1-[[(3R,5S)-1-[3-(Acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-piperidineacetic acid
• CAS NO: 189060-13-7
• Molecular Formula: C33H41ClN2O9
• Molecular Weight: 645.145
• Product Categories: Amines;Chiral Reagents;Heterocycles;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 189060-13-7.mol

Chemical Properties

• Melting Point: 194-196℃
• Boiling Point: 826.4±65.0 °C(Predicted)
• Appearance: /
• Density: 1.246±0.06 g/cm3(Predicted)
• Solubility: Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)
• PKA: 4.66±0.10(Predicted)
• CAS DataBase Reference: LAPAQUISTAT(CAS DataBase Reference)
• NIST Chemistry Reference: LAPAQUISTAT(189060-13-7)
• EPA Substance Registry System: LAPAQUISTAT(189060-13-7)

Safety Data

• Hazardous Substances Data: 189060-13-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
LAPAQUISTAT is used as an antiarteriosclerotic agent for its ability to increase collagen concentration and transform coronary plaques into fibromuscular plaques. This helps in reducing the risk of arteriosclerosis and improving cardiovascular health.
Additionally, LAPAQUISTAT is used as a cholesterol-lowering agent for its effectiveness in decreasing plasma cholesterol and triglyceride levels. This contributes to the prevention and management of various cardiovascular diseases.
Furthermore, LAPAQUISTAT is used as an inhibitor of matrix metalloproteinase-1 and plasminogen activator inhibitor-1 in the plaque. This suppression helps in reducing the risk of plaque rupture and subsequent cardiovascular events.
Lastly, LAPAQUISTAT is used as a peripheral coenzyme Q10 level enhancer, which may have potential benefits in energy production and overall cellular health.

Upstream product

• 108-24-7 acetic anhydride 
• 189059-71-0 N-[[(3R,5S)-1-(3-hydroxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]piperidine-4-acetic acid 
• 597-31-9 2,2-dimethyl-3-hydroxypropionaldehyde 
• 383661-55-0 2-[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetic acid 
• 73415-84-6 2-(piperidin-4-yl)acetic acid hydrochloride 
• 189059-65-2 ethyl 1-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]piperidine-4-acetate 
• 473987-05-2 ethyl (S)-3-[N-[4-chloro-2-(α-hydroxy-2,3-dimethoxybenzyl)phenyl]-N-(3-hydroxy-2,2-dimethylpropyl)carbamoyl]acrylate 
• 189059-61-8 ethyl (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetate 
• 189060-51-3 (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetic acid 
• 189059-60-7 (S)-5-chloro-α-(2,3-dimethoxyphenyl)-2-(3-hydroxy-2,2-dimethylpropyl)aminobenzyl alcohol 
• 189059-58-3 (-)-2-amino-5-chloro-α-(2,3-dimethoxyphenyl)benzyl alcohol 

Relevant articles and documents

HIGHLY SELECTIVE NOVEL AMIDATION METHOD

The present invention provides an industrial production method with a short process having a high yield of an aliphatic cyclic carboxamide having carboxyl group, which comprises reacting functional group-selectively using an inexpensive condensing agen

Synthesis of novel 4,1-benzoxazepine derivatives as squalene synthase inhibitors and their inhibition of cholesterol synthesis

Modification of the carboxyl group at the 3-position and introduction of protective groups to the hydroxy group of the 4,1-benzoxazepine derivative 2 (metabolite of 1) were carried out, and the inhibitory activity for squalene synthase and cholesterol syn

Benzoxazepine compounds, their production and use as lipid lowering agents

PCT No. PCT/JP96/02596 Sec. 371 Date Mar. 12, 1998 Sec. 102(e) Date Mar. 12, 1998 PCT Filed Sep. 12, 1996 PCT Pub. No. WO97/10224 PCT Pub. Date Mar. 20, 1997This invention provides new benzoxazepine compounds represented by the formula: [wherein R stands